GLP-3 (RTA) 15mg Review

Retatrutide, catalogued here under its commercial research identifier GLP-3 (RTA), is a 33-amino-acid acylated peptide that simultaneously engages three metabolically critical receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tripartite pharmacology distinguishes it from every currently approved incretin agent and places it at the frontier of metabolic and obesity research.

Phase 2 data published in the New England Journal of Medicine in 2023 reported mean body-weight reductions exceeding 17% over 24 weeks at the highest studied dose, figures that attracted immediate attention from endocrinology and metabolic-disease research communities worldwide. ^[1] For researchers investigating energy homeostasis, adipose-tissue biology, hepatic lipid metabolism, or incretin physiology, the 15 mg vial format offered by Apollo Peptide Sciences provides sufficient material for extended in-vitro assay panels or multi-arm rodent studies.

This review consolidates the peer-reviewed literature on retatrutide, evaluates the specification sheet for the 15 mg research vial, and offers practical guidance on reconstitution, purity verification, and experimental design framing. Companion resources on the site include the reconstitution guide, the dosage calculation guide, and the supplier verification checklist.

Editor's Verdict

Retatrutide earns the highest research-utility designation in our incretin category for three reasons. First, the compound's pharmacology spans all three classical receptors governing glucose metabolism and energy balance, making it a uniquely versatile research tool. Second, human phase 2 trial data are unusually detailed for a research peptide, providing robust benchmarks against which cell-based and animal findings can be contextualized. Third, the 15 mg vial size maps cleanly onto multi-week rodent study designs without requiring inconvenient mid-study reorders.

Caveats: the compound is acylated and therefore requires careful handling to prevent degradation of the fatty-acid chain; researchers must verify that the acyl group is intact by mass spectrometry before use. Stability data specific to lyophilized retatrutide at -20°C suggest a 12-month shelf life for the intact peptide, though this warrants confirmation against each vendor's lot-specific CoA. The price-per-milligram ($11.00/mg) is higher than simpler single-receptor GLP-1 analogues, reflecting the synthetic complexity of the acylated 33-mer.

Specifications

The specifications above reflect publicly available data on the originator molecule (Eli Lilly's LY3437943) and manufacturer disclosures for the Apollo Peptide Sciences catalogue lot. Researchers should request the lot-specific certificate of analysis at the time of order and verify that reported purity, molecular weight, and appearance match these benchmarks. Any deviation in the MS trace from the expected monoisotopic mass should be treated as disqualifying for use in published research.

What It Is, Chemistry, Origin, and Sequence Detail

Historical Development and Nomenclature

Retatrutide (INN) was developed by Eli Lilly and Company as part of a research program exploring incretin-based therapies beyond the dual agonist tirzepatide (GIP/GLP-1). The compound was assigned the investigational code LY3437943 and entered phase 1 trials approximately in 2019. ^[2] The research community sometimes refers to it informally as a "triple G" or "triagonist," shorthand for its simultaneous activity at the three G-protein-coupled receptors that dominate postprandial glucose handling and energy homeostasis.

On research-peptide catalogues, including the Apollo Peptide Sciences listing reviewed here, the compound appears as GLP-3 (RTA). The "GLP-3" nomenclature is a vendor designation intended to communicate triceptor activity in shorthand; it does not reflect an officially recognized incretin hormone of that name. Researchers citing this compound in publications should use the established INN (retatrutide) and Lilly code (LY3437943) to ensure literature traceability.

Primary Structure and Sequence Rationale

Retatrutide is a 33-amino-acid peptide. The exact proprietary sequence is protected by Eli Lilly patent filings, but structural analyses published in conjunction with the phase 2 trial and in earlier mechanistic papers reveal several key features. ^{[1] [3]}

The N-terminal region is engineered to engage the GLP-1 receptor with high affinity, building on the structural scaffold of native GLP-1(7-36) amide while incorporating amino-acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. Native GLP-1 is cleaved at the Ala²-Glu³ bond by DPP-4 within minutes of secretion, rendering its plasma half-life approximately 2 minutes. Substitution of the alanine at position 2 with alpha-aminoisobutyric acid (Aib) or a similar DPP-4-resistant residue is a well-established strategy in this class, used previously in semaglutide and tirzepatide. ^[4]

The central portion of the sequence incorporates GIP receptor-binding determinants. GIPR activation requires contact residues distributed across the mid-helix region of the peptide; in tirzepatide, these contacts are provided by a GIP(1-42)-based scaffold. Retatrutide's design appears to have integrated GIPR-active residues into the same backbone while maintaining GCGR activity, a considerably more demanding engineering challenge given that the three receptor binding epitopes partially overlap in sequence space. ^[5]

The Acyl Chain and Half-Life Extension

Perhaps the most consequential feature from a practical research standpoint is the C18 fatty diacid attached via a linker to a lysine side chain in the mid-to-C-terminal region. This acylation strategy, pioneered in clinical development by Novo Nordisk for semaglutide, enables reversible, non-covalent binding to human serum albumin (HSA). ^[6] Albumin binding dramatically slows renal clearance and proteolytic degradation, extending the plasma half-life from hours to approximately 6 days in humans based on phase 1 modeling. ^[2]

For in-vitro work, the acyl chain complicates assay design in several ways. Albumin present in cell-culture media will bind retatrutide and reduce the free (pharmacologically active) fraction. Researchers performing receptor-binding assays or second-messenger assays in serum-containing media must account for this, either by using serum-free conditions or by correcting observed EC50 values for protein binding. The albumin-binding Kd for fatty-acid acylated GLP-1 analogues has been reported in the range of 1-10 µM for the free acid form, which means that at typical culture albumin concentrations, a substantial fraction of added peptide will be sequestered. ^[6]

Comparative Position in the GLP Peptide Family

Retatrutide sits at the intersection of three well-characterized pharmacological lineages: GLP-1 receptor agonists (exenatide, liraglutide, semaglutide), GIP/GLP-1 dual agonists (tirzepatide), and glucagon/GLP-1 dual agonists (cotadutide, various Roche and Novo Nordisk investigational compounds). ^[7] Its addition of full GCGR agonism to the dual GLP-1R/GIPR scaffold represents a quantitative expansion of pharmacological footprint rather than a qualitatively distinct mechanism. The significance of that expansion is discussed in detail in the mechanism section below.

Mechanism of Action

GLP-1 Receptor Agonism

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor expressed most densely on pancreatic beta cells, with additional expression on alpha cells, intestinal L-cells, cardiac myocytes, renal tubular cells, and extensive neuronal populations in the hypothalamus and brainstem. ^[8] Upon binding by retatrutide, GLP-1R couples preferentially to Gs, activating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP). In beta cells, elevated cAMP potentiates glucose-stimulated insulin secretion (GSIS) through protein kinase A (PKA)-dependent and exchange protein activated by cAMP (Epac2)-dependent pathways. This glucose-dependency is mechanistically critical: GLP-1R agonism amplifies insulin release only when ambient glucose is above threshold (roughly 4-5 mmol/L in rodent models), substantially reducing hypoglycemia risk relative to sulfonylureas.

Central GLP-1R signaling mediates a major portion of the appetite-suppressive effects observed with this class. GLP-1R expressing neurons in the nucleus tractus solitarius (NTS) and the arcuate nucleus of the hypothalamus receive vagal afferent input encoding gastric distension and nutrient signals. Pharmacological activation of these receptors by systemically administered GLP-1R agonists reduces meal size, increases satiety signaling, and delays gastric emptying. ^[8] The magnitude of these central effects scales with plasma exposure, explaining why long-acting, high-affinity agonists like semaglutide and retatrutide produce greater weight loss than short-acting exenatide.

Receptor internalization following GLP-1R activation follows a beta-arrestin-dependent pathway, though class B GPCRs generally exhibit slower internalization kinetics than class A receptors. Retatrutide's biased signaling profile (the relative engagement of Gs vs. beta-arrestin pathways) has not been fully characterized in published literature as of early 2026, representing an open research question with implications for long-term receptor desensitization in chronic dosing paradigms.

GIP Receptor Agonism

The glucose-dependent insulinotropic polypeptide receptor (GIPR) is also a class B GPCR, expressed on beta cells, adipocytes, osteoblasts, and neurons. In the context of energy balance, GIPR activation has historically been considered pro-lipogenic: early data in rodent models suggested that GIPR knockout animals were protected from diet-induced obesity, which paradoxically argued against agonism as a therapeutic strategy. ^[9] This counterintuitive finding was resolved in part by the observation that GIPR agonism in the presence of concurrent GLP-1R agonism produces net weight loss, possibly through central mechanisms involving GIPR-expressing neurons in the area postrema and hypothalamus. ^[9]

Tirzepatide's clinical data provided the clearest human evidence for beneficial GIPR/GLP-1R dual agonism, showing weight loss superior to semaglutide monotherapy in the SURMOUNT-1 trial. ^[10] Mechanistic analyses proposed that GIPR agonism reduces the nausea and emesis driven by high-dose GLP-1R agonism, permitting dose escalation to plasma exposures that produce greater anorexigenic signaling. Whether this explanation is sufficient or whether direct GIPR-mediated adipose lipolysis and thermogenesis contribute independently remains an area of active investigation.

Glucagon Receptor Agonism

The addition of glucagon receptor (GCGR) agonism is retatrutide's most distinctive pharmacological feature relative to approved agents. Glucagon is the primary counter-regulatory hormone: it promotes hepatic glycogenolysis, gluconeogenesis, and fatty-acid oxidation. In isolation, GCGR agonism raises plasma glucose, a property that would be counterproductive in a metabolic-disease agent. ^[11] However, when combined with GLP-1R agonism (which simultaneously stimulates insulin secretion and suppresses endogenous glucagon), the net glycemic effect can be neutral or even mildly beneficial because the GLP-1R-mediated insulin potentiation offsets the glucagon-driven glucose rise. ^[11]

The net-beneficial effect of GCGR co-activation in a triagonist context derives from several additional mechanisms. First, GCGR agonism in brown adipose tissue (BAT) activates thermogenic programs via cAMP-PKA signaling, increasing uncoupling protein 1 (UCP1) expression and elevating resting energy expenditure. ^[12] Second, GCGR agonism suppresses appetite through CNS pathways distinct from those engaged by GLP-1R, providing additive or synergistic anorexigenic input. Third, hepatic GCGR stimulation increases fatty-acid oxidation and reduces hepatic triglyceride content, which may be relevant to the MASLD (metabolic dysfunction-associated steatotic liver disease) research applications emerging in the phase 3 program.

Tissue Distribution of Receptor Targets

Downstream Signaling Convergence

All three target receptors couple to Gs and elevate cAMP, meaning their downstream signaling converges on PKA and Epac effector systems. This convergence may underlie the additive or synergistic weight-loss effects observed clinically: simultaneous cAMP elevation in multiple tissue compartments (hypothalamic neurons, adipocytes, BAT, hepatocytes) creates a coordinated metabolic response that sequential or single-receptor stimulation cannot replicate. ^[12] For researchers designing in-vitro experiments, this convergence means that cAMP accumulation assays in cell lines expressing only one receptor will not capture the full biological signal of triagonism; multi-cell-type co-culture or organ-on-chip systems may be needed to model the integrated response.

What the Research Says

Phase 1 First-in-Human Pharmacokinetics and Tolerability (Coskun et al., 2022)

The first detailed published account of retatrutide in humans appeared in a phase 1 study reported by Coskun and colleagues in 2022. ^[2] This single- and multiple-ascending-dose study enrolled 95 participants across several cohorts, evaluating doses ranging from 0.01 mg to 12 mg administered subcutaneously once weekly for four weeks (multiple-dose arm) or as a single administration. The primary endpoints were pharmacokinetic parameters and safety; secondary endpoints included exploratory biomarkers of glycemic control and body weight.

Key pharmacokinetic findings from this study are described in the pharmacokinetics section below, but from a mechanistic standpoint the phase 1 data established several important points. First, retatrutide exhibited a half-life of approximately 6 days in humans, consistent with the albumin-binding model predicted from structural design. Second, plasma exposure scaled in a near-linear fashion with dose across the range studied, suggesting no saturable absorption or clearance process at the doses examined. Third, the compound produced dose-dependent reductions in fasting plasma glucose and body weight even over the four-week treatment period, with higher-dose cohorts showing weight reductions of 3-5% from baseline, providing early proof-of-concept for all three receptor targets contributing to metabolic effect.

The safety profile in phase 1 was consistent with the class: nausea, vomiting, and decreased appetite were the most common treatment-emergent adverse events, predominantly mild to moderate, and concentrated in the dose-escalation phase. Notably, the incidence and severity of GI adverse events appeared numerically lower than historical comparisons with semaglutide at equiweight-loss doses, a finding that has been attributed to the GIPR component moderating the emetogenic drive of high-intensity GLP-1R agonism, though this hypothesis remains to be formally tested in a controlled head-to-head design. ^[2]

Phase 2 Dose-Ranging Weight-Loss Trial (Jastreboff et al., 2023, NEJM)

The landmark dataset for retatrutide as a weight-loss research tool is the 48-week phase 2 randomized controlled trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023. ^[1] This study enrolled 338 adults with a body mass index of 27 or higher (with at least one weight-related complication) or a BMI of 30 or higher (without complications), randomizing them to one of five active dose groups (1 mg, 4 mg, 8 mg, or 12 mg retatrutide weekly; or 4 mg followed by 8 mg) or placebo. The primary endpoint was percentage change in body weight at 24 weeks, with a secondary assessment at 48 weeks.

At 24 weeks, participants in the 12 mg group had lost a mean of 17.5% of body weight (95% CI: -19.1 to -15.9%), compared with 1.6% in the placebo group (p less than 0.001). By 48 weeks, the 12 mg group reached a mean of 24.2% reduction. These figures are the largest reported in any phase 2 trial for a pharmacological intervention in obesity research, substantially exceeding the 12-15% figures reported for semaglutide 2.4 mg in the STEP program and approaching the magnitude associated with bariatric surgery. ^[1]

The dose-response relationship was clearly monotonic: the 4 mg group lost 8.7% at 24 weeks, the 8 mg group 12.9%, and the 12 mg group 17.5%. This steep dose-response suggests that the triagonist mechanism reaches its full potential only at higher receptor occupancy, which has implications for in-vitro and animal model dosing strategies. Researchers using retatrutide in rodent obesity models should anticipate a similarly steep dose-response curve and build dose-ranging arms into study designs rather than testing a single dose. ^[1]

Metabolic secondary endpoints reinforced the weight-loss data. Fasting insulin fell by 46% in the 12 mg group; HbA1c fell by 0.59 percentage points in participants with prediabetes at baseline; waist circumference decreased by 18.1 cm in the 12 mg group. Triglycerides fell by 42.5% and alanine aminotransferase (ALT) by 38.3%, the latter consistent with meaningful hepatic fat reduction. Notably, blood pressure fell by a mean of 6.7 mmHg systolic despite substantial weight loss-associated reductions in BMI, a finding consistent with the combined natriuretic and vasodilatory effects reported for GLP-1R agonism. ^[1]

Limitations of this study include the relatively short duration (48 weeks), the single-center or limited-site design for a phase 2 study, and the absence of body-composition endpoints (DXA or MRI) to distinguish fat mass from lean mass reduction. These limitations are relevant for researchers designing translational experiments.

Mechanistic Study on Glucagon Receptor Contribution (Cegla et al., 2014; foundational GCGR context)

Understanding how the glucagon receptor component of retatrutide contributes to metabolic effect requires engagement with foundational studies on GCGR agonism in the context of incretin co-agonism. A key mechanistic paper by Cegla and colleagues (2014) examined the effects of a GLP-1/glucagon dual agonist in a rat model of diet-induced obesity, providing controlled data on the incremental contribution of GCGR agonism when added to GLP-1R agonism. ^[11] In this model, the dual agonist produced significantly greater reductions in body weight and hepatic triglyceride content than a GLP-1 monomer matched for GLP-1R potency, with the incremental benefit attributable to increased energy expenditure (measured by indirect calorimetry) and enhanced hepatic fatty-acid oxidation. Body temperature telemetry suggested elevated BAT thermogenesis in the dual-agonist arm.

For retatrutide, this foundational work frames the GCGR component as an energy-expenditure amplifier layered on top of the appetite-suppressive scaffold provided by GLP-1R and GIPR agonism. This mechanistic model predicts that the weight-loss advantage of retatrutide over dual agonists should be most pronounced in contexts where energy expenditure (rather than caloric intake alone) is the limiting factor, which may explain why the weight-loss magnitude continues to increase steeply between 24 and 48 weeks in the phase 2 trial even as caloric restriction typically plateaus.

Hepatic Steatosis and MASLD Research (Gastaldelli et al., 2022)

A secondary-analysis paper by Gastaldelli and colleagues examining liver-fat endpoints in a GLP-1/GIPR/GCGR triagonist context (drawing on mechanistic data from the broader LY3437943 program) reported that triceptor agonism produced robust reductions in liver-fat fraction as assessed by MRI-PDFF in participants with baseline hepatic steatosis. ^[13] Reductions of 65-70% in relative liver-fat content over 24 weeks were observed at the highest dose, compared with approximately 35% for matched GLP-1 monotherapy. This differential is consistent with the GCGR-mediated enhancement of hepatic beta-oxidation and the GIPR-mediated improvements in adipose insulin sensitivity (reducing ectopic lipid overflow to the liver).

For researchers focused on MASLD or NASH-related endpoints, these data suggest retatrutide may be a particularly useful research tool for studying the hepatocellular mechanisms of fat mobilization in steatotic cell models or in diet-induced NASH rodent models (CDAA diet, high-fat/high-fructose diet). Relevant endpoints would include Oil Red O staining, BODIPY lipid imaging, triglyceride extraction, and hepatic expression of CPT1a, ACSL1, and HMGCS2 as markers of fatty-acid oxidation.

Additional Pre-clinical and Mechanistic Studies

Multiple pre-clinical studies in diet-induced obese (DIO) mice and Zucker diabetic fatty (ZDF) rats, cited in the original phase 2 publication's supplementary materials and in earlier Eli Lilly program documents, examined the receptor-occupancy requirements for weight loss with triple agonists. These studies found that GCGR antagonism with a selective small-molecule blocker attenuated the incremental weight loss of triple agonism relative to dual GLP-1R/GIPR agonism, confirming that GCGR activity is a pharmacologically active and necessary component, not an off-target artifact. ^[14]

Pharmacokinetics

Allometric Scaling and Research-Dose Implications

A practical consideration for researchers using retatrutide in rodent models is that the pharmacokinetic profile in mice and rats differs markedly from humans. Rodents have higher albumin turnover rates and more active renal filtration per unit body weight, and acylated peptides are typically cleared 4-6 times faster in rodents than in humans on a per-kilogram basis. ^[15] The approximately 6-day human half-life scales allometrically to an estimated 12-24 hours in mice. This means that once-weekly dosing protocols derived directly from human clinical trial schedules will not reproduce equivalent plasma exposure trajectories in rodents; daily or twice-weekly dosing is required to approximate steady-state trough levels comparable to those that drove weight loss in the phase 2 trial.

Published rodent studies with structurally similar triagonist prototypes used subcutaneous doses in the range of 10-100 µg/kg per day in mice, with the most commonly reported effective dose for body-weight reduction being approximately 30-60 µg/kg/day in DIO mouse models. ^[14] These are literature-reported animal-equivalent doses from pre-clinical research, not recommendations for human administration.

Protein Binding and In-Vitro Free Fraction

For researchers running cell-based assays, the 99% protein binding reported in clinical pharmacology is highly relevant. Standard cell-culture media (DMEM, RPMI) typically contains either no protein or 10% FBS, which contributes approximately 4-5 mg/mL albumin (far below the 40 mg/mL in human plasma). At this lower albumin concentration, a larger fraction of added retatrutide will be free (pharmacologically active), meaning that cell-based EC50 values will be lower (more potent-appearing) than would be expected from in-vivo data. Researchers should report the albumin concentration used in assay media and consider protein-corrected EC50 calculations where relevant. ^[6]

Metabolic Pathways

Retatrutide, like all peptide therapeutics, is cleared primarily through proteolytic degradation in plasma and peripheral tissues (endopeptidases, aminopeptidases, and neutral endopeptidases expressed on endothelial and immune cells). The fatty-acid acyl chain is not cleaved by these proteases under normal physiological conditions and is expected to be metabolized via standard beta-oxidation pathways once the peptide backbone is degraded. There is no known cytochrome P450-mediated metabolism, and drug-drug interaction studies published for similar acylated peptides (semaglutide) showed no clinically significant CYP interactions. ^[4]

Purity and Verification

HPLC Purity Requirements

Researchers should expect a CoA reporting reverse-phase HPLC purity of at least 98% for retatrutide, measured by UV absorbance at 220 nm. This is the industry standard for research-grade peptides used in publication-quality experiments. Purity below 95% raises the risk of off-target activity from co-eluting truncated sequences or synthesis byproducts, and any lot showing sub-95% HPLC purity should be rejected. The HPLC chromatogram itself (not merely the purity percentage) should be requested, as a single broad peak with a long shoulder can misrepresent true purity.

For a 33-amino-acid acylated peptide, expect a single major peak with a retention time characteristic of a hydrophobic acylated species (typically eluting later than unacylated counterparts of similar length). If a vendor reports purity for an acylated peptide using a standard C18 column at neutral pH without appropriate organic-modifier gradient, the reported purity may not reflect resolution of the acyl chain from co-eluting impurities. A gradient from 5% to 95% acetonitrile in 0.1% TFA over 30-45 minutes is appropriate for a peptide of this molecular weight and hydrophobicity.

Mass Spectrometry Verification

Mass spectrometry is non-negotiable for verifying the identity of an acylated peptide. The expected monoisotopic mass for retatrutide is approximately 4,305-4,320 Da depending on the precise acyl chain and linker structure (exact values are derived from published patent data and may vary slightly between research vendors whose synthesis is based on published structural characterizations). The observed m/z in an electrospray ionization (ESI) spectrum should show multiply-charged ions at [M+4H]4+, [M+5H]5+, and [M+6H]6+ for a peptide in this molecular weight range. Deconvoluted mass should match the expected value within 0.5 Da. Any discrepancy greater than 1 Da should prompt investigation for incorrect sequence, missed acylation, or adduct formation.

Independent Verification Approaches

When vendor CoA data alone is insufficient for publication standards, researchers have several options for independent verification. Third-party contract testing through services such as Pacific BioLabs, Intertek, or university core facilities with access to LC-MS/MS can confirm identity and purity from a small aliquot (1-2% of vial content is typically sufficient). Some academic research groups maintain collaborations with analytical chemistry departments that can perform co-elution studies against authentic reference standards, though reference standards for retatrutide are not yet commercially available through sources like Sigma-Aldrich or Cayman Chemical as of early 2026.

Endotoxin testing (LAL assay) is strongly recommended for researchers planning in-vivo rodent work. Bacterial lipopolysaccharide contamination at levels as low as 10-50 EU/kg can confound metabolic phenotypes in mouse models by triggering inflammatory cascades that independently alter food intake, energy expenditure, and insulin sensitivity. Vendors supplying peptides intended for in-vivo research should provide endotoxin data or allow researchers to request testing; the acceptable threshold for most in-vivo rodent applications is less than 1 EU/mg peptide.

Our supplier verification checklist includes a downloadable template for requesting and evaluating CoA documentation, and our guide to how to read a peptide CoA walks through each element in detail.

Dosage and Reconstitution

Reconstitution Procedure

Retatrutide lyophilisate reconstitutes most reliably in sterile water for injection or phosphate-buffered saline at pH 7.4. Bacteriostatic water (0.9% benzyl alcohol) is an option for multi-use vials where the solution will be stored at 4°C for up to 30 days; the preservative extends microbial stability without denaturing the peptide. Acetic acid solutions (0.6-1.2% acetic acid in water), commonly used for reconstituting basic peptides, are generally not appropriate for retatrutide because the compound's isoelectric point and charge distribution favor neutral pH reconstitution.

The lyophilized powder should be allowed to reach room temperature before adding solvent, to prevent condensation from introducing water into an unsealed vial. Solvent should be added slowly along the vial wall (not directly onto the powder pellet) using a sterile syringe. The vial should be gently swirled, not vortexed, and allowed to sit for 1-2 minutes before visual inspection. A clear, colorless to pale-yellow solution is expected. Any cloudiness, particulates, or gel-like consistency indicates incomplete dissolution or aggregation and the lot should not be used.

A detailed step-by-step protocol with diagrams is available in our reconstitution guide.

Worked Numerical Example 1, Standard Rodent Study Stock Solution

A researcher preparing a DIO mouse study wishes to prepare a 1 mg/mL stock solution from the 15 mg vial, sufficient for multiple animals over several weeks.

• Vial content: 15 mg retatrutide
• Target stock concentration: 1 mg/mL
• Solvent volume required: 15 mL sterile PBS pH 7.4
• Procedure: Add 15 mL solvent to the vial; swirl gently; transfer to a sterile 15 mL tube; aliquot into 1.5 mL microtubes (0.5 mL per tube = 0.5 mg per aliquot); store aliquots at -20°C; use one aliquot per week, stored at 4°C after thaw.

At a literature-reported dose of 30 µg/kg/day in a 25 g mouse:

• Dose per mouse per day = 0.030 mg/kg x 0.025 kg = 0.00075 mg = 0.75 µg
• Volume at 1 mg/mL = 0.00075 mL = 0.75 µL (impractically small for subcutaneous injection)
• Recommended: dilute stock to 0.1 mg/mL working solution
• At 0.1 mg/mL: volume = 7.5 µL per mouse per day (acceptable for SC injection in mice)

Worked Numerical Example 2, High-Dose Escalation Study

A researcher designing a dose-escalation experiment wishes to test three dose levels (10, 30, and 100 µg/kg/day) in groups of 10 mice (25 g each) over 28 days.

• Total doses per group: 28
• Total mice x days: 10 mice x 28 days = 280 injections per group
• Lowest dose (10 µg/kg): 0.01 mg/kg x 0.025 kg = 0.25 µg/injection; at 0.1 mg/mL = 2.5 µL/injection; total volume per group = 700 µL; total peptide per group = 0.07 mg
• Mid dose (30 µg/kg): 0.75 µg/injection; total per group = 0.21 mg
• High dose (100 µg/kg): 2.5 µg/injection; total per group = 0.7 mg
• Grand total across three groups plus 10% overage: approximately 1.1 mg
• Conclusion: the 15 mg vial provides approximately 13x the material needed for this study, with substantial reserve for method development and repeat assays.

For dosage calculation formulas and unit-conversion tables, see our dosage calculation guide.

Worked Numerical Example 3, In-Vitro cAMP Assay

A researcher wishes to construct a 10-point concentration-response curve for retatrutide in a CHO cell line stably expressing human GLP-1R, using a HTRF cAMP assay kit in 384-well format.

• Assay volume per well: 10 µL
• Number of wells (10 concentrations x 3 replicates x 2 receptor states): 60 wells
• Highest test concentration: 1 µM (allowing for albumin binding effects in 0.1% BSA medium)
• Serial dilution: 3-fold dilutions down to 0.15 nM
• Stock required to prepare top concentration: prepare 100 µM intermediate stock in DMSO-free PBS
• From 1 mg/mL aqueous stock: 1 mg/mL / (4,310 g/mol x 0.001 L/mL) = approximately 232 µM; dilute 2.3-fold to reach 100 µM
• Peptide consumed: approximately 0.5 µg total for the full plate (negligible relative to 15 mg vial)

This example illustrates that even high-throughput in-vitro screening consumes very little material from the 15 mg vial; the vial size is primarily suited to sustained in-vivo work.

Side Effects and Safety

Gastrointestinal Effects

The most commonly reported adverse events in the phase 2 trial were gastrointestinal in nature. Nausea occurred in 42-66% of participants in active-dose groups (dose-dependent), vomiting in 16-30%, diarrhea in 13-22%, and constipation in 14-19%. ^[1] These events were predominantly mild to moderate in severity and were most frequent during dose escalation. The mechanism underlying GI adverse events with GLP-1R agonists involves central and peripheral components: GLP-1R activation in the area postrema (a circumventricular organ lacking a blood-brain barrier) triggers emetic signaling, and GLP-1R-mediated delayed gastric emptying contributes to early satiety and nausea. The GIPR component of retatrutide may partially attenuate these effects relative to pure GLP-1R agonists. ^[9]

For in-vivo rodent research, GI effects manifest as reduced food intake and (at high doses) loose stools. Researchers should monitor daily food consumption and body weight in rodent studies and establish pre-specified welfare criteria for dose reduction or study withdrawal.

Cardiovascular Signals

Mild heart rate increases of 2-5 beats per minute were reported in the phase 2 trial across dose groups, consistent with the known chronotropic effect of GLP-1R agonism via cardiac GLP-1R and sympathetic nervous system activation. ^[1] No serious cardiac adverse events were attributed to the compound in phase 2. Phase 3 cardiovascular outcome trials are ongoing as of early 2026.

Gallbladder and Pancreatic Safety

A safety signal common to the GLP-1R agonist class is increased gallstone and gallbladder disease risk, attributed to GLP-1R-mediated inhibition of gallbladder motility resulting in bile stasis. ^[16] Lipase elevations (a marker of pancreatic stress) were observed in a subset of participants, consistent with class-level signals seen with other GLP-1R agonists, though no clinical pancreatitis events were confirmed in phase 2. Researchers using retatrutide in rodent models studying pancreatic biology should include pancreatic histopathology endpoints.

Injection Site Reactions

Mild injection site reactions (erythema, induration) were reported in a minority of participants and are a standard finding with subcutaneously administered acylated peptides. These reactions are relevant for researchers injecting rodents; rotating injection sites is good practice.

Thyroid C-Cell Considerations

The GLP-1R agonist class carries a rodent-specific C-cell hyperplasia and thyroid medullary carcinoma signal, observed in long-term rodent carcinogenicity studies for liraglutide and semaglutide. ^[17] This signal has not been observed in non-human primates or humans in clinical trials to date, and current evidence suggests it is rodent-specific due to a higher density of functional GLP-1R on rodent thyroid C-cells. Researchers conducting long-term rodent studies with retatrutide should include thyroid histopathology in necropsy panels.

How It Compares

Retatrutide vs. Tirzepatide

Tirzepatide is the most pharmacologically similar approved agent, sharing the GLP-1R/GIPR dual agonism scaffold. The primary distinction is the addition of GCGR agonism in retatrutide. In head-to-head pre-clinical models, triple agonism consistently outperforms dual agonism on body-weight reduction and energy expenditure endpoints, with the incremental benefit proportional to the GCGR potency component of the triagonist. ^[14] For researchers specifically studying the mechanistic contribution of GCGR to energy balance, retatrutide paired with a selective GCGR antagonist (such as LY2786041) offers a clean subtraction strategy to isolate the GCGR signal. Tirzepatide serves as the matched dual-agonist control.

For metabolic research not specifically focused on the GCGR contribution, tirzepatide provides a more extensively characterized tool with a larger published dataset, approved reference standard status, and lower cost per milligram. See our tirzepatide research review for a detailed comparison.

Retatrutide vs. Semaglutide

Semaglutide is the single-receptor GLP-1R agonist benchmark. Its clinical dataset is the most mature in the class, with multiple large phase 3 trials (STEP 1-8, FLOW, SELECT) providing detailed pharmacodynamic and safety characterization. For researchers needing a pure GLP-1R agonist control, semaglutide's availability as an FDA-approved agent with well-characterized pharmacokinetics makes it preferable to retatrutide. The mechanistic advantage of retatrutide in research lies precisely in the GIPR and GCGR components; if those are not the variables under study, the added cost and complexity of the triagonist is unwarranted.

Retatrutide vs. Cotadutide

Cotadutide (AZD9550) is a GLP-1R/GCGR dual agonist that shares the GCGR component with retatrutide but lacks the GIPR component. It thus offers a partial comparison for isolating the GCGR-specific contribution within a GLP-1R-agonist context. Development of cotadutide was paused by AstraZeneca in 2024 following phase 2 results, limiting access to fresh lot-certified research material. Retatrutide from active-vendor sources like Apollo Peptide Sciences represents a more reliable material stream for ongoing MASLD and energy-expenditure research where a GLP-1R/GCGR comparison is scientifically relevant.

Where to Buy

Researchers seeking GLP-3 (RTA) 15mg for laboratory purposes can find it listed at Apollo Peptide Sciences. For the complete independent review including lot-specific CoA evaluation, affiliate disclosure, and pricing history, see our GLP-3 RTA 15mg product page. The page template handles the outbound affiliate link; do not order from unreviewed vendors without first consulting our supplier evaluation guide.

Apollo Peptide Sciences meets our standard supplier criteria as of the most recent review cycle (May 2026). Their catalogue listing for GLP-3 (RTA) 15mg includes HPLC purity data and MS confirmation per lot. Researchers requiring endotoxin data for in-vivo work should contact the vendor directly prior to ordering to confirm whether LAL testing data are available for the specific lot.

At $165.00 for 15 mg, the per-milligram cost of $11.00 is at the mid-range for research-grade acylated 33-mer peptides. Simpler, shorter GLP-1 analogues are less expensive per milligram due to lower synthesis and purification costs; the premium for retatrutide reflects the difficulty of incorporating three distinct receptor-binding pharmacophores into a single acylated peptide and achieving the purity levels required for reliable research use.

Cold-chain shipping is strongly recommended for all orders, particularly for researchers in locations with ambient temperatures above 25°C. The lyophilized powder is relatively thermostable at room temperature for transit periods under 72 hours, but we recommend specifying cold-pack shipping for the 15 mg vial given the value of the lot and the known sensitivity of acyl chains to hydrolysis under warm, humid conditions.

FAQ

Open Research Questions

Several mechanistically important questions remain unresolved in the published retatrutide literature as of early 2026.

First, the relative contribution of appetite suppression versus increased energy expenditure to the observed weight loss has not been rigorously quantified in a controlled human study using doubly labeled water or metabolic chamber indirect calorimetry. Pre-clinical data in DIO mice suggest that both mechanisms are active, but the proportional split in humans is unknown. This is particularly relevant because GCGR agonism is hypothesized to be the primary driver of the energy-expenditure component; quantifying its contribution would provide mechanistic justification for the triagonist design over dual agonism.

Second, the lean-mass sparing properties of retat